CN115666583A - 用于治疗sars-cov-2病毒的糖皮质激素受体(gr)调节剂 - Google Patents

用于治疗sars-cov-2病毒的糖皮质激素受体(gr)调节剂 Download PDF

Info

Publication number
CN115666583A
CN115666583A CN202180031406.4A CN202180031406A CN115666583A CN 115666583 A CN115666583 A CN 115666583A CN 202180031406 A CN202180031406 A CN 202180031406A CN 115666583 A CN115666583 A CN 115666583A
Authority
CN
China
Prior art keywords
sars
cov
icam3
cell
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180031406.4A
Other languages
English (en)
Chinese (zh)
Inventor
T·迭舍尔
S·W·麦凯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AVM Biotechnology LLC
Original Assignee
AVM Biotechnology LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AVM Biotechnology LLC filed Critical AVM Biotechnology LLC
Publication of CN115666583A publication Critical patent/CN115666583A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN202180031406.4A 2020-04-29 2021-04-28 用于治疗sars-cov-2病毒的糖皮质激素受体(gr)调节剂 Pending CN115666583A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063017199P 2020-04-29 2020-04-29
US63/017,199 2020-04-29
PCT/US2021/029608 WO2021222385A1 (en) 2020-04-29 2021-04-28 Glucocorticoid receptor (gr) modulators for treating a sars-cov-2 virus

Publications (1)

Publication Number Publication Date
CN115666583A true CN115666583A (zh) 2023-01-31

Family

ID=76270026

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180031406.4A Pending CN115666583A (zh) 2020-04-29 2021-04-28 用于治疗sars-cov-2病毒的糖皮质激素受体(gr)调节剂

Country Status (7)

Country Link
US (1) US20230172950A1 (enExample)
EP (1) EP4142736A1 (enExample)
JP (1) JP2023524434A (enExample)
KR (1) KR20230015927A (enExample)
CN (1) CN115666583A (enExample)
BR (1) BR112022021691A2 (enExample)
WO (1) WO2021222385A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024540319A (ja) * 2021-11-05 2024-10-31 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 肺粘膜炎症の処置のための低分子量ヒアルロン酸の使用
CN114028571B (zh) * 2021-11-18 2023-04-28 中国医学科学院基础医学研究所 含氮双膦酸盐联合糖皮质激素在预防或治疗病毒性肺炎中的应用
CN114099481B (zh) * 2022-01-28 2022-05-24 深圳湾实验室 雾化吸入型糖皮质激素纳米药物及其制备方法和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3490605B1 (en) 2017-04-01 2023-06-07 AVM Biotechnology, LLC Replacement of cytotoxic preconditioning before cellular immunotherapy
EP3488851A1 (en) * 2018-10-03 2019-05-29 AVM Biotechnology, LLC Immunoablative therapies
CA3168378A1 (en) * 2020-02-28 2021-09-02 Avm Biotechnology, Llc Lypmphocyte population and methods for producing same

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
MATSUYAMA等: "The inhaled corticosteroid ciclesonide blocks coronavirus RNA replication by targeting viral NSP15", 《BIORXIV》, 12 March 2020 (2020-03-12), pages 2 - 3 *
侯静静;龚慧;赵翊畅;徐萍;张毕奎;颜苗;: "新型冠状病毒肺炎治疗中的药物不良反应与防治", 药学进展, no. 02, 25 February 2020 (2020-02-25), pages 153 *
高亭;徐仰玲;何小鹏;马玉娟;王李珍;蒋引娣;吴长刚;张文明;陈剑辉;: "40例新型冠状病毒肺炎的流行病学及临床特征分析", 中国呼吸与危重监护杂志, no. 02, 25 March 2020 (2020-03-25), pages 54 - 59 *

Also Published As

Publication number Publication date
BR112022021691A2 (pt) 2022-12-20
KR20230015927A (ko) 2023-01-31
JP2023524434A (ja) 2023-06-12
WO2021222385A1 (en) 2021-11-04
US20230172950A1 (en) 2023-06-08
EP4142736A1 (en) 2023-03-08

Similar Documents

Publication Publication Date Title
Qu et al. BCG vaccination strategies against tuberculosis: updates and perspectives
US11419879B2 (en) Methods for treating and preventing viral infections
Zhong et al. Immunomodulatory role of estrogen in ischemic stroke: neuroinflammation and effect of sex
Papenfuss et al. Estriol generates tolerogenic dendritic cells in vivo that protect against autoimmunity
Ryu et al. Blood coagulation protein fibrinogen promotes autoimmunity and demyelination via chemokine release and antigen presentation
Johnson et al. Etoposide selectively ablates activated T cells to control the immunoregulatory disorder hemophagocytic lymphohistiocytosis
Tahamtan et al. Effects of cannabinoids and their receptors on viral infections
Zhu et al. Innate and adaptive immune response in SARS-CoV-2 infection-Current perspectives
Song et al. CCR7-CCL19/CCL21-regulated dendritic cells are responsible for effectiveness of sublingual vaccination
Bajwa et al. Immune mechanisms and novel pharmacological therapies of acute kidney injury
Brahmachari et al. Sodium benzoate, a food additive and a metabolite of cinnamon, modifies T cells at multiple steps and inhibits adoptive transfer of experimental allergic encephalomyelitis
Kaushik et al. TLR4 as a therapeutic target for respiratory and neurological complications of SARS-CoV-2
CN115666583A (zh) 用于治疗sars-cov-2病毒的糖皮质激素受体(gr)调节剂
Di Cosimo et al. Immune checkpoint inhibitors: a physiology-driven approach to the treatment of coronavirus disease 2019
Zhang et al. Tick-borne encephalitis virus induces chemokine RANTES expression via activation of IRF-3 pathway
Ma et al. Alopecia areata: pathogenesis, diagnosis, and therapies
Myers et al. Combined CD137 (4-1BB) and adjuvant therapy generates a developing pool of peptide-specific CD8 memory T cells
Cukalac et al. The influenza virus–specific CTL Immunodominance hierarchy in mice is determined by the relative frequency of high-avidity T cells
Marcondes et al. Enrichment and persistence of virus-specific CTL in the brain of simian immunodeficiency virus-infected monkeys is associated with a unique cytokine environment
Choi et al. Indispensable role of CX3CR1+ dendritic cells in regulation of virus-induced neuroinflammation through rapid development of antiviral immunity in peripheral lymphoid tissues
He et al. PKHB1 peptide induces antiviral effects through induction of immunogenic cell death in herpes simplex keratitis
Palakeel et al. An outlook on the etiopathogenesis of pulmonary hypertension in HIV
Hamana et al. Amelioration of experimental autoimmune encephalomyelitis in mice by interferon-beta gene therapy, using a long-term expression plasmid vector
Xu et al. Severe acute respiratory syndrome coronavirus 2 and male reproduction: relationship, explanations, and clinical remedies
Nyariki et al. Coenzyme Q10 exhibits anti-inflammatory and immune-modulatory thereby decelerating the occurrence of experimental cerebral malaria

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination